Pyxis Oncology, Inc. (PYXS)
| Market Cap | 98.50M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -87.95M |
| Shares Out | 32.83M |
| EPS (ttm) | -4.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,512 |
| Open | 2.94 |
| Previous Close | 3.00 |
| Day's Range | 2.87 - 3.10 |
| 52-Week Range | 1.96 - 19.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 13.77 (+359.0%) |
| Earnings Date | Aug 12, 2022 |
About PYXS
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for PYXS stock is "Buy." The 12-month stock price forecast is 13.77, which is an increase of 359.00% from the latest price.
News
Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update
• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, reported o...
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today anno...
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat can...
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat can...
Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat c...
Pyxis Oncology Announces Leadership Changes
- Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer -
Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022...
- Data highlight PYX-106's differentiated activity profile and antitumor activity in an in vivo mouse model -
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology
- Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $10 million upfron...
Pyxis Oncology Provides Corporate and Financial Update
Announces Expansion of Novel Immuno-Oncology Therapeutic Portfolio with Addition of Anti-Siglec-15 In-licensed from Biosion (PYX-106)
Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022
CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing next-generation therapeutics for difficult to treat ...
Pyxis to be Added to Russell 2000® Index
CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers,...
Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer
Industry veteran brings expertise in corporate strategy and business development to Pyxis team Industry veteran brings expertise in corporate strategy and business development to Pyxis team
Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer
WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer
Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers,...
Pyxis Oncology to Present at the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual portion ...
Pyxis Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficu...